ArticleERJ open research2019
Impact of
Article in ERJ open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07275905 (A Phase 1, Open-label, Randomized, Pilot and Feasibility Trial to Evaluate the Safety and Tolerability of the Achromobacter-targeting Bacteriophage Cocktail, AchromoPhage, Among Persons With Cystic Fibrosis and Chronic Achromobacter Lung Infections), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1, Open-label, Randomized, Pilot and Feasibility Trial to Evaluate the Safety and Tolerability of the Achromobacter-targeting Bacteriophage Cocktail, AchromoPhage, Among Persons With Cystic Fibrosis and Chronic Achromobacter Lung Infections: The AchromoPhage Trial
Who cites it
28 citing papers in PubMed, 35 citations in OpenAlex.
- Review
- Epidemiology ofNew microbes and new infections · 2026Article
- Genomic insights into the resistome, mobilome and functional adaptation ofMicrobial genomics · 2026Article
- Article
- Achromobacter xylosoxidans modulates Pseudomonas aeruginosa virulence through a complex multi-target competition.Scientific reports · 2025Article
- Achromobacter spp.: Emerging pathogens in the cystic fibrosis lung.PLoS pathogens · 2025Article
- Investigating Bacterial Invasion of Highly Differentiated Human Bronchial Epithelial Cell Barriers.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis.Clinical microbiology reviews · 2024Review
- Accelerated Lung Function Decline and Mucus-Microbe Evolution in Chronic Obstructive Pulmonary Disease.American journal of respiratory and critical care medicine · 2024Observational
- Prevalence and variability of siderophore production in theMicrobiology spectrum · 2024Article
- Pathogenesis ofInfection and immunity · 2023Article
- Exoproducts of the Most CommonMicrobiology spectrum · 2023Article
- Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis.Children (Basel, Switzerland) · 2022Article
- TheMicrobiology spectrum · 2022Article
- Characterization of theFrontiers in cellular and infection microbiology · 2022Article
- Role of Efflux in Antibiotic Resistance ofFrontiers in microbiology · 2022Article
- Article
- In Vitro Activity of 22 Antibiotics againstMicroorganisms · 2021Article
- Effect ofAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of
methodsThis was a case-control retrospective study performed at a single CF centre in Lille, France. Data for 36 patients with CF who had at least one sputum culture positive for
resultsCompared with the
conclusion
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.